Do Hedge Funds Love Karyopharm Therapeutics Inc (KPTI)?

As industrywide interest jumped, key money managers were leading the bulls’ herd. Citadel Investment Group, led by Ken Griffin, created the biggest position in Karyopharm Therapeutics Inc (NASDAQ:KPTI). According to its latest 13F filing, the fund had $0.3 million invested in the company at the end of the quarter. David E. Shaw’s D E Shaw also initiated a $0.3 million position during the quarter. The following funds were also among the new KPTI investors: Peter Rathjens, Bruce Clarke and John Campbell’s Arrowstreet Capital and Paul Tudor Jones’s Tudor Investment Corp.

Let’s check out hedge fund activity in other stocks similar to Karyopharm Therapeutics Inc (NASDAQ:KPTI). We will take a look at Bank Mutual Corporation (NASDAQ:BKMU), Corenergy Infrastructure Trust Inc (NYSE:CORR), Digimarc Corp (NASDAQ:DMRC), and Protagonist Therapeutics Inc (NASDAQ:PTGX). This group of stocks’ market valuations are closest to KPTI’s market valuation.

As you can see these stocks had an average of 6 hedge funds with bullish positions and the average amount invested in these stocks was $42 million. That figure was also $42 million in KPTI’s case. Corenergy Infrastructure Trust Inc (NYSE:CORR) is the most popular stock in this table. On the other hand Protagonist Therapeutics Inc (NASDAQ:PTGX) is the least popular one with only 5 bullish hedge fund positions. Compared to these stocks Karyopharm Therapeutics Inc (NASDAQ:KPTI) is more popular among hedge funds. Considering that hedge funds are fond of this stock in relation to its market cap peers, it may be a good idea to analyze it in detail and potentially include it in your portfolio.

Disclosure: None